JAMA

Research: Surgeons, Hospitals Involved in Exceptional Research Have Lower Patient Mortality Rates, Fewer Complications

Retrieved on: 
Wednesday, April 3, 2024
Software, Research, Oncology, Technology, Hospitals, Health Technology, Science, Surgery, Cardiology, Neurology, Practice Management, Health, JAMA, Evidence-based medicine, Surgeon, Urology, Environment, Physician, Impact factor, Hospital, Mortality, Patient, General surgery, Neurosurgery, Ear, Woman, Otorhinolaryngology, Male, Publication, Novant Health, Harvard Business Review, Nose, Surgical oncology, Medicare, PubMed, Elective surgery, Gastroenterology

Surgeons and hospitals who conduct the most leading-edge research achieve lower rates of patient mortality and complications than those who do not, according to findings released today by Avant-garde Health.

Key Points: 
  • Surgeons and hospitals who conduct the most leading-edge research achieve lower rates of patient mortality and complications than those who do not, according to findings released today by Avant-garde Health.
  • Patients under the care of top surgeon-researchers showed a 5% lower rate of post-discharge complications and a 5% lower rate of mortality, within 30 days post-discharge, according to the research.
  • All 4,500 physicians and 350 hospitals being honored are listed on the Research All-Stars site .
  • In addition, a significant portion of the top surgeon-researchers – 47.1% on average – served as the leading or senior authors of their research.

Breakthrough Results of NIH-Sponsored Study of Syn-One Test® as a Skin-Based Diagnostic Tool for Parkinson’s Disease and Related Disorders Published in the Journal of the American Medical Association

Retrieved on: 
Wednesday, March 20, 2024
Research, Neurology, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, JAMA, Lewy body, Diagnosis, Harvard Medical School, American Medical Association, DLB, MSA, Disease, PD, Multiple system atrophy, Alpha-synuclein, Physician, Journal, CND, MD, NIH, Synucleinopathy, Skin, Pathology, Bangladesh Technical Education Board, Medicare, PAF, Dementia, Phosphorylation, Medical imaging

The primary goal of this study was to define the positivity rate of skin biopsies to detect P-SYN deposition in clinically confirmed cases of PD, MSA, DLB, and PAF.

Key Points: 
  • The primary goal of this study was to define the positivity rate of skin biopsies to detect P-SYN deposition in clinically confirmed cases of PD, MSA, DLB, and PAF.
  • The proportion of patients with P-SYN was 92.7% in those with PD, 98.2% in those with MSA, 96.0% in those with DLB, and 100% in those with PAF.
  • Future disease-modifying therapies will require convenient, accurate, and precise diagnostic tools to reach the right patients at the right time across a wide array of communities.
  • “The publication of this important NIH-sponsored study is one big step forward with many more milestones to come.”

Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

Retrieved on: 
Wednesday, March 13, 2024
Alternative Medicine, Mental Health, Health, FDA, Clinical Trials, Pharmaceutical, Biotechnology, JAMA, Depression, Disability, Conference, BTD, Breakthrough therapy, Massachusetts General Hospital, Inc., Psychiatry, Clinical, Grammatical mood, Appetite, MDD, Data analysis, Patient, Knowledge, Disease, Causality, Sleep, Anhedonia, DNB, DSM-IV codes, MBBS, Suicidal ideation, Behavior, Cognition, Event, Hospital, Drug development, Safety, Injury, Multimedia, Plasma protein binding, Sadness, Lancet, BMJ, Pharmaceutical industry

If approved by the FDA, CYB003 would be the first known adjunctive psychedelic-based therapeutic for the treatment of MDD.

Key Points: 
  • If approved by the FDA, CYB003 would be the first known adjunctive psychedelic-based therapeutic for the treatment of MDD.
  • The designation of CYB003 as a breakthrough therapy acknowledges the significant unmet medical need for more effective treatments of MDD and supports CYB003’s potential for significant improvements over existing therapies.
  • With the robust durability data from our Phase 2 study in hand, we are ready to move forward expeditiously.
  • (2022) Response to acute monotherapy for major depressive disorder in randomized, placebo-controlled trials submitted to the US Food and Drug Administration: individual participant data analysis.

Battling the opioid epidemic: New research shows access to opioid use disorder treatment in emergency rooms saves lives

Retrieved on: 
Tuesday, March 26, 2024
JAMA, EDS, American Medical Association, Survival, Addiction medicine, AHS, Patient, OUD, Journal, Research, Buprenorphine, Opioid use disorder, Emergency department, Drug, ED, Alameda Health System, Pharmaceutical industry

The research points to emergency rooms as critical gateways for providers to reach and treat patients with opioid use disorder.

Key Points: 
  • The research points to emergency rooms as critical gateways for providers to reach and treat patients with opioid use disorder.
  • Emergency departments are often the lowest-barrier access point for people seeking immediate health care.
  • This research shows that initiation of buprenorphine in the emergency department, combined with linkage to outpatient treatment, saves lives.
  • The Bridge Clinic at AHS is at the forefront of bringing opioid use disorder treatment to patients in Alameda County.

HiLabs Announces Closing of $39 Million Series B Financing to Advance its AI-powered Data Management Solutions for Healthcare Organizations

Retrieved on: 
Thursday, March 14, 2024
JAMA, American Medical Association, Growth, CFO, Patient, Journal, AI, Partnership, Directory

BETHESDA, Md., March 14, 2024 /PRNewswire/ -- HiLabs, a leading provider of AI-powered solutions to manage dirty data, unlocking its hidden potential for healthcare transformation, today announced a $39 million Series B financing. The round was led by Denali Growth Partners and Eight Roads Ventures, with participation from F-Prime Capital. The capital raise follows rapid customer adoption of its healthcare data ingestion, cleansing, and enrichment platform, MCheck™, and will support continued enhancement of the technology as well as recruitment of top-tier talent and expansion of its product teams.

Key Points: 
  • BETHESDA, Md., March 14, 2024 /PRNewswire/ -- HiLabs , a leading provider of AI-powered solutions to manage dirty data, unlocking its hidden potential for healthcare transformation, today announced a $39 million Series B financing.
  • Founded in 2014, HiLabs' mission is to ensure timely access to clean data for payers, providers, and patients at a time when healthcare organizations worldwide are transitioning toward data-driven decision-making.
  • HiLabs' cloud-based MCheck platform ingests, cleans, and enriches critical healthcare information, resulting in significant reduction in healthcare organizations' operational costs and improvement in patient outcomes.
  • The company's provider directory management solution is live in most US states, analyzing data of over 80% of the country's healthcare providers.

Sutter Health and Charles R. Drew University Partner to Address Physician Shortage and Health Inequities Across California

Retrieved on: 
Wednesday, March 6, 2024
Sutter Health, Student, CDU, Investment, Physician, Partnership, JAMA, Health, Organization, Patient, PubMed, Medicine, Health equity, Research, Nursing

"This unique collaboration marks a significant step toward building a more equitable health care system in California,” said Dr. David M. Carlisle, president and CEO of Charles R. Drew University.

Key Points: 
  • "This unique collaboration marks a significant step toward building a more equitable health care system in California,” said Dr. David M. Carlisle, president and CEO of Charles R. Drew University.
  • Additionally, it will fund HEARE over the next five years to help accelerate interventions that address root causes of inequities.
  • Sutter Health and CDU will also explore additional opportunities to broaden the partnership and train more physicians with future initiatives.
  • This investment is part of Sutter’s broader commitment to address California’s growing physician shortage and persistent health inequities by enhancing access to culturally competent care for under-represented populations.

Scilex Holding Company Announces Publication in Anesthesiology Journal of Results from an Investigator-Initiated Research Study Using ZTlido® for the Treatment of Chronic Neck Pain¹

Retrieved on: 
Tuesday, February 20, 2024
PALO, Prevalence, Neck pain, Lidocaine, Physical medicine and rehabilitation, Neurology, Anesthesiology, American Medical Association, JAMA, Outline of health sciences, Disability, Chronic pain, Behavioural sciences, COVID, Patient, Journal, Neck, Psychiatry, Clutch (eggs), Rehabilitation, Pharmaceutical industry

PALO ALTO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced publication in Anesthesiology Journal of results from an investigator-initiated research study using ZTlido® for the treatment of chronic neck pain.

Key Points: 
  • PALO ALTO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced publication in Anesthesiology Journal of results from an investigator-initiated research study using ZTlido® for the treatment of chronic neck pain.
  • The primary outcome measure was mean reduction in average neck pain coupled with the Patient Global Impression of Change.
  • Neck pain, or cervicalgia, is one of the most common pain presentations in U.S. and the 4th leading cause of disability.
  • According to a 2020 JAMA publication (Journal of the American Medical Association), the U.S. low back and neck pain market is estimated at $134.5B.4

Mastercard Expands HealthLock Benefit to Millions of U.S. Cardholders, Enabling Automated Detection of Potential Medical Claims Errors, Overbilling and Fraud

Retrieved on: 
Tuesday, March 5, 2024
Software, Banking, Internet, Professional Services, Data Management, Technology, Security, Health Technology, Health Insurance, Insurance, Finance, Health, Small business, Fraud, American Medical Association, Mastercard, HSA, Patient, Journal, JAMA

HealthLock helps protect a user’s medical data from data breaches and organizes deductibles, claims and provider information in one secure, digital space.

Key Points: 
  • HealthLock helps protect a user’s medical data from data breaches and organizes deductibles, claims and provider information in one secure, digital space.
  • As new claims come in, the platform analyzes and flags each one for potential errors, fraud or overbilling.
  • Data from the Journal of the American Medical Association shows medical overbilling, fraud and abuse cost Americans hundreds of billions of dollars annually1.
  • They will have access to HealthLock’s Medical Claims Monitor, which monitors and protects your medical data privacy against fraud, at no cost.

Northwell Health Researcher Shows Vitamin D Could Improve Insulin-producing Cells in Children With Type 1 Diabetes

Retrieved on: 
Tuesday, March 5, 2024
Children, Diabetes, Health, General Health, Pharmaceutical, Research, Fitness & Nutrition, Consumer, Science, Teens, Parenting, Paper, Ergocalciferol, Multimedia, Medical research, Vitamin D, MBA, American Medical Association, Cell, Northwell Health, Cohen, Endocrinology, Patient, Journal, Pancreas, Insulin, Disease, Pediatrics, JAMA, C-peptide, Credit, Dietary supplement

To help children and young people navigate type 1 diabetes, new research from Cohen Children’s Medical Center and The Feinstein Institutes for Medical Research at Northwell Health shows that taking vitamin D could help improve the function of insulin-producing cells.

Key Points: 
  • To help children and young people navigate type 1 diabetes, new research from Cohen Children’s Medical Center and The Feinstein Institutes for Medical Research at Northwell Health shows that taking vitamin D could help improve the function of insulin-producing cells.
  • View the full release here: https://www.businesswire.com/news/home/20240305266724/en/
    Dr. Benjamin Nwosu’s study shows that vitamin D could be an easier and more affordable option to help adolescents living with type 1 diabetes.
  • The research showed that by taking high-dose vitamin D, patients saw improvement in the function of insulin-producing cells which could extend the “honeymoon phase” of type 1 diabetes.
  • This research shows that by adding vitamin D, which is inexpensive and easy to obtain, one can make this phase of diabetes last longer.

Addressing New York's Youth Mental Health Crisis, Montefiore Announces Plans for New Pediatric Inpatient Psychiatry Unit

Retrieved on: 
Wednesday, March 6, 2024
New York State Assembly, Anxiety, Mental health, New Yorker, Adolescence, Suicidal ideation, Education, HRSA, Montefiore Medical Center, Hospital, Bed, Assembly, Mental, JAMA, Psychosis, Behavioural sciences, Depression, Patient, Pediatrics, Child, Psychiatry, Trauma, Environment, Travel, Intensive outpatient program, Nursing

BRONX, N.Y., March 6, 2024 /PRNewswire/ -- Montefiore today announced plans for a new pediatric inpatient psychiatry unit adding a new care option to address the unmet urgent behavioral and mental health needs of children and adolescents in the Bronx. The Montefiore Einstein Center for Children's Mental Health of the Children's Hospital at Montefiore Einstein will be funded in part by a nearly $6 million appropriation to Montefiore spearheaded by New York State Assembly Speaker Carl Heastie and Assembly Member Michael Benedetto. The 21-bed child and adolescent unit will be located within the New York City Children's Center (NYCCC) campus adjacent to the Albert Einstein College of Medicine and will serve as a model for urban pediatric inpatient psychiatric services. The new program will physically and programmatically extend the capacity of CHAM to provide a full range of medical and behavioral health services for youth in the region. The proposed center will be designed to provide best-in-class intensive treatment for youth with serious behavioral health conditions including severe depression, anxiety, trauma, suicidal thoughts, psychosis and other acute psychiatric conditions.

Key Points: 
  • BRONX, N.Y., March 6, 2024 /PRNewswire/ -- Montefiore today announced plans for a new pediatric inpatient psychiatry unit adding a new care option to address the unmet urgent behavioral and mental health needs of children and adolescents in the Bronx.
  • The new program will physically and programmatically extend the capacity of CHAM to provide a full range of medical and behavioral health services for youth in the region.
  • As a leading health system in New York renowned for delivering exceptional care, I am confident that Montefiore will exceed in tackling mental health disparities with the new pediatric psychiatry unit," said New York State Assembly Speaker Carl Heastie.
  • The Montefiore pediatric psychiatry unit will provide 24/7 best-in-class care and access to comprehensive evaluation and care administered by mental health professionals expert in pediatric psychiatry.